Therma Bright Inc. is advancing in the compression therapy market with its Venowave VW5, a portable, battery-powered device addressing healthcare needs in an aging population. The company secured Medicare and Medicaid reimbursement approvals rapidly, obtaining a HCPCS Level II code within 60 days. Since October 1, 2024, more than 110 Venowave VW5 units have been deployed across the United States, with 25 units already receiving full reimbursement through commercial and federal healthcare networks.
The Venowave VW5 offers distinct advantages as a compact, lightweight device weighing 250 grams, designed to improve vascular and lymphatic flow in lower limbs. Clinical studies demonstrate its effectiveness, showing a 64% increase in venous blood flow within two minutes and an 88% increase after 50 minutes of use. The device stands out as the only Medicare-approved mobile mechanical compression system under HCPCS code E0683, qualifying for reimbursement under ten medical indications. Its FDA designation as Durable Medical Equipment and ability to be used across multiple patients enhance its market appeal.
Strategic partnerships are driving Therma Bright's market expansion. The company signed a Letter of Intent with DME Authority, a Nashville-based distributor, committing to purchase $6 million worth of Venowave VW5 units in the first six months of 2025. Additionally, Valor Medical Solutions placed an initial order for 100 units, with plans to increase orders biweekly. These developments position the company to capitalize on the growing compression therapy market, projected to expand from $4.18 billion in 2024 to $6.72 billion by 2033, representing a compound annual growth rate of 7.3%.
Rob Fia, CEO of Therma Bright, emphasized the company's potential, noting that rapid reimbursement processing and increasing patient demand suggest significant revenue growth in 2025 and beyond. As healthcare evolves, Therma Bright's innovative approach to compression therapy represents a promising development in non-invasive medical treatment technologies, with its Venowave VW5 addressing critical needs through portable, clinically effective solutions.
